Botulinum Toxin Injections

Published 03/17/2026

Chemodenervation refers to "the use of chemical agents to produce neuromuscular blockade for the purpose of selective weakening of specific muscles or muscle groups." Neurotoxins, as well as other chemical agents, are used for this purpose.

Botulinum toxin, a neurotoxin produced by clostridium botulinum, produces a clinical effect by blocking the release of neurotransmitters, principally acetylcholine, from nerve endings. There are currently four botulinum neurotoxins available in the US with different FDA-approved indication(s): three distinct serotype A botulinum toxin therapeutic products, onabotulinumtoxinA (BOTOX®), abobotulinumtoxinA (DYSPORT®) and incobotulinumtoxinA (XEOMIN®), and the serotype B botulinum toxin product, rimabotulinumtoxinB (MYOBLOC®). These products are not interchangeable, and it is the physician's responsibility to select the appropriate product and dose in accordance with FDA-approval indications for use, compendia-supported uses, and supported by peer reviewed specific scientific literature.

Coverage

Medicare allows coverage and payment for only those services that are considered to be reasonable and necessary for the diagnosis or treatment of illness or injury, or to improve the functioning of a malformed body member. Botulinum toxin injections are not covered for cosmetic purposes. Palmetto GBA Local Coverage Determination (LCD) Botulinum Toxin Injections L39836 outlines conditions where botulinum toxin injections may be covered/indicated. The coverage indications are specific and include limitations. Details of coverage indications are available by clicking on the link to L39836in the reference section included with this updated article.

Dosage and Frequency

In addition to coverage limitations, there are also dosage and frequency limitations. Botulinum toxin injections have a variable lasting beneficial effect from twelve to sixteen weeks, following which the procedure may need to be repeated. It is appropriate to inject the lowest clinically effective dose at the greatest feasible interval that results in the desired clinical result. Services performed for excessive frequency are not medically necessary. Frequency is considered excessive when services are performed more frequently than 12 weeks and the reason for additional services is not justified by documentation.

Documentation

Legible documentation to support medical necessity must be present for each date of service billed on the claim and should include the following elements:

  • Specific botulinum toxin used
  • Dosage of toxin used (including dosage in units per site)
  • A complete description of the site(s) injected
  • A covered diagnosis (however, when a form of botulinum toxin is used for an indication that is not supported by FDA-approval and/or compendia support, a physician statement in the medical record stating the reason or reasons why the unsupported form was used is also required)
  • Support of the clinical effectiveness of the injections, noting date of last injection, if applicable
  • Support for the medical necessity of electromyography or stimulation guidance procedures if performed

References

Botulinum Toxin Injections Documentation Checklist

Table 1: Botulinum Toxin Injections Documentation Checklist
Botulinum Toxin Injections Documentation Checklist Yes No N/A
Is the request an expedited review for Botox injection?      
Does the patient have a covered diagnosis?      
Is there a documented history of symptoms supporting the covered diagnosis?      
Documentation to support dosage of botulinum toxin requested.      
Documentation to support botulinum toxin injection will not be given more frequently than every 12 weeks.      
Does the documentation support the medical necessity of the specific botulinum toxin injection requested?      
Documentation of an objective clinical assessment at baseline and at each follow-up assessment using the same scale during each assessment.      
Blepharospasms/Blepharospasms associated with Orofacial Dystonia/Hemifacial Spasms

Is the requested procedure for an initial botulinum toxin injection for blepharospasms (blepharospasm associated with orofacial dystonia or hemifacial spasms)?

  • Does documentation support clinical features consistent with one of the above diagnoses?

    And:
     
  • Does documentation support chronic blepharospasms of at least 30 days, and/or moderate to severe blepharospasms associated with orofacial dystonia or hemifacial spasms measured on an objective clinical scale at baseline?

    And:
     
  • Does the documentation support a covered botulinum toxin therapy as the accepted first line of treatment for any of the above diagnosis?
      
       
Is the requested procedure for a subsequent botulinum toxin injection for Blepharospasms, Blepharospasm associated with orofacial dystonia or Hemifacial Spasms? 
  • If yes, does documentation include an informed clinical decision regarding a repeat injection?

    And:
     
  • Does documentation include a reassessment of the severity, frequency and/or persistence of symptoms associated with blepharospasm, blepharospasm associated with orofacial dystonia or hemifacial spasms measured on an objective clinical scale at baseline and after each procedure using the same scale?

    And:
     
  • Was the initial treatment considered sufficient and same dosage recommended or was the initial treatment considered insufficient (does not last longer than two months) and administration of an increased dose is recommended?
      
       
Chronic Migraines/Headaches
Is the requested procedure for an initial botulinum toxin injection for Chronic Migraines?      
Does the medical record include a history of headaches that have occurred greater than or equal to 15 days per month?

And...		      
Does documentation support migraine headaches have occurred greater than or equal to eight days per month and last for a duration greater than or equal to four hours a day?

And...		      

Does documentation support that chronic headaches have been present for at least three months? 

And...

      
Does documentation support that the beneficiary has completed at least a two-month trial of at least one agent in any two of the medication classes OR has contraindication to the following medication classes (antidepressants, beta blockers, calcium channel blockers or antiepileptics)?

And...		      

Does documentation support the beneficiary is using a calcitonin gene related peptide (CGRP)?

  • Does documentation support a reduction in the number of migraine days per month but still having migraines requiring additional therapy for prevention?

And...

      
Does documentation support headaches are causing an objective significant functional disability?

And...		      
Does documentation support that headaches are moderate to severe in intensity with typical migraine headache characteristics?      
Is the requested procedure for a subsequent botulinum toxin injection for Chronic Migraines?      
Does the documentation support the total number of chronic migraine headache days and/or frequency of total chronic migraine headache episodes have demonstrated a greater than or equal to 50% reduction in migraine headache days or episodes per month?

And...		      
Does the documentation support minimum important change and significant reduction of headache-related disability and objective improvement in functioning?

And...		      
Does documentation support that biobehavioral therapy has been implemented as appropriate?

And...		      

Is botulinum toxin being used concurrently with a CGRP agent for migraine prophylaxis?

  • Has the beneficiary had further reduction in the overall number of migraine days or reduction in number of severe migraine days per month compared to monotherapy with the initial agent (either botulinum toxin or the CGRP agent)?
      
Does documentation contain a limitation to receiving botulinum toxin injections (e.g., multiple procedures being performed on the same day, dosages exceeding recommendations, etc.)?      

Was this article helpful?